Hubungan Antara Pemakaian Efavirenz Dengan Efek Samping Neuropsikiatri Pada Pasien Hiv/aids

Abstract

Background: HIV/AIDS has been a global problem. Antiretroviral therapy is currently an effective therapy for HIV/AIDS. Efavirenz is an antiretroviral agent which commonly cause neuropsychiatric adverse events.Aim: To investigate the association between efavirenz and neuropsychiatric adverse events.Methods: This cross-sectional study included 43 subjects (24 men and 19 women). Twenty subjects used efavirenz and twenty three subjects didn't use efavirenz. Neuropsychiatric adverse events were assessed with SMMSE for cognitive impairment; DASS 21 for depression disorder, anxiety disorder, and stress disorder; PQ-16 for psychosis; and PSQI for sleep disturbance.Results: Neuropsychiatric adverse events were more common in patients using efavirenz. Fisher's exact test between efavirenz and cognitive disturbance showed significant association (p= 0,039). The significant result was also showed between efavirenz and anxiety disorder (p= 0,017) as well as between efavirenz and psychosis (p= 0,017). Chi-square test between efavirenz and sleep disturbance showed significant association (p= 0,017). The association test between efavirenz and depression disorder along with association test between efavirenz and stress disorder showed no significant result.Conclusions: Efavirenz was significantly associated with cognitive impairment, anxiety, psychosis, and sleep disturbance. There was no significant association of efavirenz with depression disorder and stress disorder